SURVYR

DGX

Quest Diagnostics Incorporated
$242.56
−$0.39 (0.16%)Oct 27 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-7%+5%+17%+28%+40%Oct 2025Oct 2026Apr 202652w high $248.8452w low $171.18
DGXSPY
Wall St. Highest PT $275.00 (+13.4%) Wall St. Avg PT $254.73 (+5.0%)
$171$199$227$255$283POC $195Hi $275Avg $255
Underwater Drawdown %Max DD -11.6%Current -1.6%
0.0%-11.6%
Relative Strength vs SPY+23.3% vs SPYOutperforming
+32%0%-32%
1W
+$5.44 (2.29%)
1M
+$7.12 (3.02%)
3M
+$7.49 (3.19%)
6M
+$49.02 (25.33%)
YTD
+$71.90 (42.13%)
1Y
+$65.28 (36.82%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
15 analysts · mean score 2.06
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$242.56
Average target$254.73
+$12.17 (+5.0%) upsideaverage target vs current price
CurrentAverageMedian
Low$235.00
Median$254.73
High$275.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-07 · Barclays reiterated Overweight on DGX
Reiterated
2026-09-21 · Truist Securities reiterated Hold on DGX
Reiterated
2026-09-08 · UBS reiterated Neutral on DGX
Reiterated
2026-07-28 · JP Morgan reiterated Neutral on DGX
Reiterated
2026-07-25 · UBS reiterated Neutral on DGX
Reiterated
2026-07-24 · Mizuho reiterated Outperform on DGX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$26.7B
P/E (last 12 months)24.1
P/E (next 12 months, estimated)20.2
52-week range$171.18 – $248.84
Revenue growth (latest quarter vs a year ago)+10.0%
Dividend yield1.42%
Analyst consensusBuy (15)
Average analyst price target$254.73 (+5%)

What they do

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
69th percentile in sector
B
12-1 return: +34.2%
Percentile within its GICS sector across the S&P 1500.
Growth
60th percentile in sector
B-
Revenue growth (YoY): +10.2%
Percentile within its GICS sector across the S&P 1500.
Value
52nd percentile in sector
C+
Forward E/P: 5.1% · EBITDA/EV: 7.1%
Percentile within its GICS sector across the S&P 1500.
Profitability
58th percentile in sector
B-
Profit margin: +9.2% · Return on equity: +14.6%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 145 of 499 · 12-month momentum 28.3%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

DGX earningsReported Oct 22, 2026▲ Above estimates
Results · Before the open
EPS actual$3.00
EPS estimate$2.87
Surprise+4.4%
RevenueNot in our data yet

Revenue for this quarter is not in our data yet. It arrives with the quarterly filing.

Next report
Tue Feb 9, 2027Before the open
EPS consensus$2.68 range $2.63–$2.74
Revenue consensus$3.0B 11 analysts
Last 4 quarters · EPS vs estimate
Oct 22, 2026$3.00est $2.87+4.4%Above estimates
Jul 23, 2026$3.12est $2.82+10.5%Above estimates
Apr 21, 2026$2.50est $2.37+5.6%Above estimates
Feb 10, 2026$2.42est $2.36+2.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 11:12:37 ET
25-0125-0425-0725-1026-0226-0426-0726-100.003.12
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$3.0B+10.2%
2026-03-31$2.9B–
2025-12-31$2.8B–
2025-09-30$2.8B–
2025-06-30$2.8B–

Recent dividends

2026-10-06: $0.860 · 2026-07-08: $0.860 · 2026-04-06: $0.860 · 2026-01-13: $0.800 · 2025-10-03: $0.800 · 2025-07-07: $0.800 · 2025-04-07: $0.800 · 2025-01-14: $0.750

News & catalysts

More news
Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?
Zacks · 15h ago
Western Digital's Q1 Earnings & Revenues Beat, Dividend Hiked by 17%
Zacks · Oct 23
Quest Diagnostics: 3 Key Takeaways for Long-Term Investors
Nasdaq · Oct 22
Quest Diagnostics (DGX) Q3 2026 Earnings Call Transcript
Nasdaq · Oct 22
Quest Diagnostics Q3 26 Earnings Conference Call At 8:30 AM ET
Nasdaq · Oct 22
Rating changes
Reiterated
2026-10-07 · Barclays reiterated Overweight on DGX
Reiterated
2026-09-21 · Truist Securities reiterated Hold on DGX
Reiterated
2026-09-08 · UBS reiterated Neutral on DGX
Reiterated
2026-07-28 · JP Morgan reiterated Neutral on DGX
Reiterated
2026-07-25 · UBS reiterated Neutral on DGX
Reiterated
2026-07-24 · Mizuho reiterated Outperform on DGX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Davis J. E.
Director, CEO and President · 2026-09-01
Sell
$2.4M
Prevoznik Michael E
SVP & General Counsel · 2026-08-28
Sell
$105.1K
Prevoznik Michael E
SVP & General Counsel · 2026-08-28
Sell
$1.5M
Prevoznik Michael E
SVP & General Counsel · 2026-08-28
Sell
$3.9M
Delaney Mark E
SVP & Chief Commercial Officer · 2026-07-28
Sell
$376.3K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-24 11:12:37 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026